Research And Preparation Of HPMC-Based Matrix Sustained Release Tablets Of Artificial Musk

Coronary heart disease(CHD) is one of most serious diseases that dose great harm to the health of human being . According of the estimate of our country , the death rate of CHD is 0.2% that higher than USA,Canada, France and Japan's. At the present time, glonoine is the most popular drug used to treat CHD, but it has short half-life and many side-effects. The aim of this project is intending to adopt new technique, prepare Artificial Musk into quicker, higher, longer effect peroral sustained release tablets(abbreviated AMSRT). It can reduce the patient's taking medicine frequency and enhance bioavailability.It is reported that Artificial Musk and natural Musk have the similar action with glonoin in curing CHD. And they haven't the glonoin's side effects. In the past research of this project, quicker, longer effect AMSRT has been prepared successfully, Adding drug of fast release part which released fast(<1h) to reach the effective haemal concentration, controlled the symptom of CHD quickly. Whereafter the drug of sustained release part release slowly,keeping the effective haemal concentration in a long time(>10hr).In this project, muscone, the mainly effective substance in Artificial Musk, has been analysed as factor,.many new ingredients were tested and used. On the decided release condition in vitro, tablets at the lth, 5th and 10th hour, the cumulative released percentage of the matrices sustained release tablets were 51. 07% , 72. 86% , 92. 14%.Set up the quality standard of AMSRT preliminary.DB-1 capillary column gas chromatogram and mass spectrum uniting apparatus was used to determinate Muscone in the matrix tablet.High pure helium gas is carrier and iso-psoralen is internal reference. Result: linear range of muscone is 0.01136~0.3667mg/ml, r= 0.9994. Recycle rate is 99.01%, RSD=4.95%. Precision in one day is RSD=3.85% and precision of days is RSD=2.20%.The mean content of Muscone in a tablet is 3.33mg(RSD=2.54%). Examine the preparation stability by FDA method.The losing rate of Muscone is 7.36%,so the preparation has a good stability. Period of validity can be set 2 years preliminary.In our research, quicker, longer effect AMSRT was prepared successful which primo dosage was released rapidly, delayed part controlled released according with the first kinetics equation,maintain effective haemal concentration in a long time...